Includes data on NfL changes after initiation of fingolimod, ofatumumab, ocrelizumab, natalizumab, alemtuzumab and oral cladribine.
11 slides
SLIDE LIBRARY
Re-evaluating the balance of efficacy and safety with disease-modifying therapies
June 8, 2023Includes data on early use of high-efficacy DMTs, risks of undertreatment of MS, safety issues and de-risking anti-CD20 therapy during long-term use.
16 slides
ECTRIMS 2022 SLIDE DECK
November 10, 2022Selected highlights from the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Amsterdam, The Netherlands
26-28 October 2022
62 slides with notes
Scientific review:
Dr. Daniel Selchen, Senior Consultant, BARLO MS centre, St. Michael’s Hospital, Toronto, Canada Read More
How much B cell suppression is needed in MS?
May 30, 2022Includes a comparison of anti-CD20 therapies (rituximab, ocrelizumab, ofatumumab), depth and duration of B cell suppression, time to B cell reconstitution, and current data on reduced-dose regimens, extended-interval dosing and personalized dosing.
14 slides
ECTRIMS 2021 SLIDE DECK
October 22, 2021Selected highlights from ECTRIMS 2021
Virtual Congress – 13-15 October 2021
52 slides
Scientific review:
Dr. Daniel Selchen, Senior Consultant, BARLO MS centre, St. Michael’s Hospital, Toronto, Canada
Read More